http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 24 Aug 2026 17:11:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+21++Filed+by%3A+Hively+Brad/26969077.html si-local-file:///var/storage/secattach/20260824/26969077.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+21++Filed+by%3A+Hively+Brad/26969077.html Mon, 24 Aug 2026 17:11:00 -0400 O.21802973 TOI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+21++Filed+by%3A+Hively+Brad/26969077.html si-local-file:///var/storage/secattach/20260824/26969077.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+21++Filed+by%3A+Hively+Brad/26969077.html Mon, 24 Aug 2026 17:11:00 -0400 O.21802973 TOI http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+20/26962534.html si-local-file:///var/storage/secattach/20260821/26962534.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+20/26962534.html Fri, 21 Aug 2026 17:25:00 -0400 O.21802973 STLN TOI http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+20/26962534.html si-local-file:///var/storage/secattach/20260821/26962534.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+20/26962534.html Fri, 21 Aug 2026 17:25:00 -0400 O.21802973 STLN TOI http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+20/26962534.html si-local-file:///var/storage/secattach/20260821/26962534.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+20/26962534.html Fri, 21 Aug 2026 17:25:00 -0400 O.21802973 STLN TOI http://www.streetinsider.com/SEC+Filings/Form++144++++++++Starling+Oncology%2C+Inc.++++++++++++++++Filed+by%3A+Hively+Brad/26961897.html si-local-file:///var/storage/secattach/20260821/26961897.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Starling+Oncology%2C+Inc.++++++++++++++++Filed+by%3A+Hively+Brad/26961897.html Fri, 21 Aug 2026 16:36:00 -0400 O.21802973 STLN TOI http://www.streetinsider.com/SEC+Filings/Form++144++++++++Starling+Oncology%2C+Inc.++++++++++++++++Filed+by%3A+Hively+Brad/26961897.html si-local-file:///var/storage/secattach/20260821/26961897.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Starling+Oncology%2C+Inc.++++++++++++++++Filed+by%3A+Hively+Brad/26961897.html Fri, 21 Aug 2026 16:36:00 -0400 O.21802973 STLN TOI http://www.streetinsider.com/SEC+Filings/Form++144++++++++Starling+Oncology%2C+Inc.++++++++++++++++Filed+by%3A+Hively+Brad/26961897.html si-local-file:///var/storage/secattach/20260821/26961897.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Starling+Oncology%2C+Inc.++++++++++++++++Filed+by%3A+Hively+Brad/26961897.html Fri, 21 Aug 2026 16:36:00 -0400 O.21802973 STLN TOI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+13++Filed+by%3A+Chernett+Jorey/26936212.html si-local-file:///var/storage/secattach/20260817/26936212.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+13++Filed+by%3A+Chernett+Jorey/26936212.html Mon, 17 Aug 2026 10:13:00 -0400 O.21802973 TOI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+13++Filed+by%3A+Chernett+Jorey/26936212.html si-local-file:///var/storage/secattach/20260817/26936212.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+13++Filed+by%3A+Chernett+Jorey/26936212.html Mon, 17 Aug 2026 10:13:00 -0400 O.21802973 TOI http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Starling+Oncology%2C+Inc.+++For%3A+Jun+30/26884895.html si-local-file:///var/storage/secattach/20260806/26884895.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Starling+Oncology%2C+Inc.+++For%3A+Jun+30/26884895.html Thu, 06 Aug 2026 16:36:00 -0400 O.21802973 STLN TOI http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Starling+Oncology%2C+Inc.+++For%3A+Jun+30/26884895.html si-local-file:///var/storage/secattach/20260806/26884895.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Starling+Oncology%2C+Inc.+++For%3A+Jun+30/26884895.html Thu, 06 Aug 2026 16:36:00 -0400 O.21802973 STLN TOI http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Starling+Oncology%2C+Inc.+++For%3A+Jun+30/26884895.html si-local-file:///var/storage/secattach/20260806/26884895.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Starling+Oncology%2C+Inc.+++For%3A+Jun+30/26884895.html Thu, 06 Aug 2026 16:36:00 -0400 O.21802973 STLN TOI http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+06/26884805.html si-local-file:///var/storage/secattach/20260806/26884805.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+06/26884805.html Thu, 06 Aug 2026 16:33:00 -0400 O.21802973 STLN TOI http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+06/26884805.html si-local-file:///var/storage/secattach/20260806/26884805.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+06/26884805.html Thu, 06 Aug 2026 16:33:00 -0400 O.21802973 STLN TOI http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+06/26884805.html si-local-file:///var/storage/secattach/20260806/26884805.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+06/26884805.html Thu, 06 Aug 2026 16:33:00 -0400 O.21802973 STLN TOI http://www.streetinsider.com/Press+Releases/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html <p align="justify">CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it&apos;s full-year 2026 guidance.</p> <p align="justify"><strong>Recent Operational Highlights</strong></p> <ul type="disc"><li style="text-align:left;">Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the http://www.streetinsider.com/Press+Releases/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html Thu, 06 Aug 2026 16:14:00 -0400 O.21802973 STLN TOI TOIIW http://www.streetinsider.com/Press+Releases/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html <p align="justify">CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it&apos;s full-year 2026 guidance.</p> <p align="justify"><strong>Recent Operational Highlights</strong></p> <ul type="disc"><li style="text-align:left;">Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the http://www.streetinsider.com/Press+Releases/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html Thu, 06 Aug 2026 16:14:00 -0400 O.21802973 STLN TOI TOIIW http://www.streetinsider.com/Press+Releases/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html <p align="justify">CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it&apos;s full-year 2026 guidance.</p> <p align="justify"><strong>Recent Operational Highlights</strong></p> <ul type="disc"><li style="text-align:left;">Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the http://www.streetinsider.com/Press+Releases/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html Thu, 06 Aug 2026 16:14:00 -0400 O.21802973 STLN TOI TOIIW http://www.streetinsider.com/Press+Releases/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html <p align="justify">CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it&apos;s full-year 2026 guidance.</p> <p align="justify"><strong>Recent Operational Highlights</strong></p> <ul type="disc"><li style="text-align:left;">Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the http://www.streetinsider.com/Press+Releases/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html Thu, 06 Aug 2026 16:14:00 -0400 O.21802973 STLN TOI TOIIW http://www.streetinsider.com/Globe+Newswire/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html <p align="justify">CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it&apos;s full-year 2026 guidance.</p> <p align="justify"><strong>Recent Operational Highlights</strong></p> <ul type="disc"><li style="text-align:left;">Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the http://www.streetinsider.com/Globe+Newswire/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html Thu, 06 Aug 2026 16:14:00 -0400 O.21802973 STLN TOI TOIIW http://www.streetinsider.com/Globe+Newswire/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html <p align="justify">CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it&apos;s full-year 2026 guidance.</p> <p align="justify"><strong>Recent Operational Highlights</strong></p> <ul type="disc"><li style="text-align:left;">Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the http://www.streetinsider.com/Globe+Newswire/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html Thu, 06 Aug 2026 16:14:00 -0400 O.21802973 STLN TOI TOIIW http://www.streetinsider.com/Globe+Newswire/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html <p align="justify">CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it&apos;s full-year 2026 guidance.</p> <p align="justify"><strong>Recent Operational Highlights</strong></p> <ul type="disc"><li style="text-align:left;">Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the http://www.streetinsider.com/Globe+Newswire/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html Thu, 06 Aug 2026 16:14:00 -0400 O.21802973 STLN TOI TOIIW http://www.streetinsider.com/Globe+Newswire/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html <p align="justify">CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it&apos;s full-year 2026 guidance.</p> <p align="justify"><strong>Recent Operational Highlights</strong></p> <ul type="disc"><li style="text-align:left;">Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the http://www.streetinsider.com/Globe+Newswire/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html Thu, 06 Aug 2026 16:14:00 -0400 O.21802973 STLN TOI TOIIW http://www.streetinsider.com/Press+Releases/Constellation+Software+Inc.+and+Topicus.com+Inc.+Announce+Results+for+Topicus.com+Inc.+for+the+Second+Quarter+Ended+June+30%2C+2026/26875652.html <p align="justify">TORONTO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) in a joint release with Constellation Software Inc. (TSX:CSU) today announced financial results for Topicus.com Inc. (“Topicus” or the “Company”) for the second quarter ended June 30, 2026. Please note that all amounts referred to in this press release are in Euros unless otherwise stated.</p> <p align="justify">The following press release should be read in conjunction with the Company’s Unaudited Condensed Consolidated Interim Financial Statements for the three and six months ended June 30, 2026 and the accompanying notes, our Management’s Discussion and Analysis for the three http://www.streetinsider.com/Press+Releases/Constellation+Software+Inc.+and+Topicus.com+Inc.+Announce+Results+for+Topicus.com+Inc.+for+the+Second+Quarter+Ended+June+30%2C+2026/26875652.html Wed, 05 Aug 2026 17:02:00 -0400 CSU O.00792313 O.49875685 TOI